top of page

Groundbreaking Study Shows Promise for Cannabis-Based Treatment in Alzheimer’s Agitation

In a groundbreaking development, IGC Pharma, Inc. has announced promising interim results from its Phase 2 clinical trial for IGC-AD1, a pioneering THC-based formulation targeting agitation in dementia associated with Alzheimer’s disease.

Alzheimer's disease presents not only cognitive challenges but also mood and behavior disturbances, with agitation being a particularly burdensome symptom affecting millions in the U.S. alone. The study, aimed at addressing this pressing issue, demonstrated a clinically significant reduction in agitation within just two weeks of treatment compared to a placebo.

The innovative nature of IGC-AD1 lies in its ability to target neuroinflammation and CB1 receptor dysfunction, leveraging THC, a principal psychoactive cannabinoid found in cannabis. The results not only showed a noticeable improvement in patients but also indicated a large magnitude of difference between the active and placebo groups, as measured by the Cohen Mansfield Agitation Inventory.

What makes this development even more compelling is the safety profile of IGC-AD1, with over 1,000 oral doses administered and no dose-limiting adverse events observed thus far. This underscores the potential of IGC-AD1 as a viable treatment option, especially in contrast to existing therapies like Brexpiprazole, which comes with notable side effects.

Ram Mukunda, CEO of IGC Pharma, expressed excitement over the interim results, emphasizing the significant impact this treatment could have on improving the quality of life for Alzheimer's patients and their caregivers.

Beyond IGC-AD1, IGC Pharma is actively pursuing a robust pipeline of drug candidates targeting various hallmarks of Alzheimer's disease, from neuroinflammation to Aβ plaques and neurofibrillary tangles. With a mission to transform the landscape of Alzheimer's treatment, the company's dedication to innovation and research is evident.

As we await further updates and the completion of the clinical trial, the potential of cannabis-based treatments in addressing the complex symptoms of Alzheimer's disease offers hope for millions worldwide. Stay tuned as IGC Pharma continues to pave the way for groundbreaking advancements in Alzheimer's therapy.

But, why wait? If you are looking to find solutions for symptoms of agitation associated with Alzheimer's, schedule a Deep Dive with Coach Chela on how you can implement cannabis medicine for your loved one living with dementia, including low dose THC and CBD.

7 views0 comments


bottom of page